Volume 14, Issue 3 (Summer 2025)
aumj 2025, 14(3): 246-256 |
Back to browse issues page
Ethics code: IR.SBMU.RETECH.REC.1402.539
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Omidi F, Sayyadi S, Omidian M M, Vaziri-harami R, Delkash P, Kharazmi A B. Tofacitinib and Cardiovascular outcome in Rheumatoid Arthritis Patients: An Updated Systematic Review and Meta-Analysis. aumj 2025; 14 (3) :246-256
URL: http://aums.abzums.ac.ir/article-1-1894-en.html
URL: http://aums.abzums.ac.ir/article-1-1894-en.html
Fatemeh Omidi1 
, Shahram Sayyadi2 , Mohammad Mahdi Omidian3 
, Roya Vaziri-harami4 , Parisa Delkash *5 , Amir Behnam Kharazmi6
, Shahram Sayyadi2 , Mohammad Mahdi Omidian3 , Roya Vaziri-harami4 , Parisa Delkash *5 , Amir Behnam Kharazmi6
1- Department of Cardiovascular, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Anesthesiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Orthopedic, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Psychiatry, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Department of Rheumatology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,Parisa.delkash@yahoo.com
6- Department of Internal Medicine, pulmonology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Anesthesiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Department of Orthopedic, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Psychiatry, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5- Department of Rheumatology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,
6- Department of Internal Medicine, pulmonology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (581 Views)
Introduction: Rheumatoid arthritis is a chronic inflammatory disease that predominantly affects the joints and can significantly impact the quality of life of patients. Tofacitinib is recognized as a key medication in managing this condition. However, concerns about the potential side effects of this drug, especially its impact on cardiovascular health, still exist.
Methods: International databases including PubMed, Embase, and Cochrane Central were searched for relevant articles. The quality of the studies was assessed using the Cochrane risk of bias assessment tool. Data were statistically analyzed using a random-effects model and the CMA software version 3.
Results: This study, based on data from five trials involving 3,111 rheumatoid arthritis patients, investigated the relationship between Tofacitinib at 5 mg and 10 mg doses and cardiovascular events. In the 5 mg Tofacitinib group, 8 out of 1,897 patients experienced cardiovascular events (odds ratio of 2.95 with a 95% confidence interval from 0.5 to 17.1). In the 10 mg Tofacitinib group, only 4 out of 1,895 patients reported these events (odds ratio of 1.83 with a 95% confidence interval ranging from 0.3 to 9.3).
Conclusion: Tofacitinib is recognized as an effective drug in controlling the symptoms of rheumatoid arthritis. However, our results indicate that the use of this drug may be associated with an increased risk of cardiovascular events. Although these differences were not statistically significant, they emphasize the importance of closer monitoring of patients taking Tofacitinib. Clinical decisions should consider the risk of cardiovascular events, and conducting intervention studies with larger sample sizes and longer follow-ups is essential.
Keywords: Cardiovascular disorders, Rheumatoid Arthritis, Drug side effects, Systematic Review, Tofacitinib
Type of Study: Research |
Subject:
Special
Received: 2025/02/08 | Accepted: 2025/02/18 | Published: 2025/05/25
Received: 2025/02/08 | Accepted: 2025/02/18 | Published: 2025/05/25
References
1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356-61. [DOI:10.1038/nature01661] [PMID]
2. Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nature Reviews Rheumatology. 2022;18(10):591-602. [DOI:10.1038/s41584-022-00827-y] [PMID]
3. Singh JA. Risks and benefits of Janus kinase inhibitors in rheumatoid arthritis-past, present, and future. Mass Medical Soc; 2022. p. 387-9. [DOI:10.1056/NEJMe2117663] [PMID]
4. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Current opinion in chemical biology. 2016;32:29-33. [DOI:10.1016/j.cbpa.2016.03.006] [PMID]
5. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez J-B, Dowty ME, et al. The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318-28.
6. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Annals of the rheumatic diseases. 2013;72(suppl 2):ii111-ii5. [DOI:10.1136/annrheumdis-2012-202576] [PMID] []
7. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2019;58(6):953-62.
https://doi.org/10.1093/rheumatology/kez002 [DOI:10.1093/rheumatology/key339] []
8. Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chemical Research in Toxicology. 2019;33(1):125-36. [DOI:10.1021/acs.chemrestox.9b00387] [PMID]
9. Halacoglu J, Shea LA. Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis. Journal of cardiovascular translational research. 2020;13:878-90. [DOI:10.1007/s12265-020-09964-9] [PMID]
10. Kotyla PJ, Islam MA, Engelmann M. Clinical Aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. International journal of molecular sciences. 2020;21(19):7390. [DOI:10.3390/ijms21197390] [PMID] []
11. Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi MC, Luciano N, et al. Safety of JAK inhibitors: A real-life multicenter retrospective cohort study. The Journal of Rheumatology. 2023. [DOI:10.3899/jrheum.2023-0145] [PMID]
12. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77:1987-2001. [DOI:10.1007/s40265-017-0835-9] [PMID]
13. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. New England Journal of Medicine. 2022;386(4):316-26. [DOI:10.1056/NEJMoa2109927] [PMID]
14. Kaur K, Kalra S, Kaushal S. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis. Clinical therapeutics. 2014;36(7):1074-86. [DOI:10.1016/j.clinthera.2014.06.018] [PMID]
15. Jung J-Y, Lee E, Kim J-W, Suh C-H, Kim H-A. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: From the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. 2023;41:1034-41. [DOI:10.55563/clinexprheumatol/6fcyza]
16. Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390-400.
17. Castañeda OM, Romero FJ, Salinas A, Citera G, Mysler E, Rillo O, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis in Latin America compared with the rest of the world population. JCR: Journal of Clinical Rheumatology. 2017;23(4):193-9. [DOI:10.1097/RHU.0000000000000498] [PMID]
18. Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):485-95.
19. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377-86. [DOI:10.1056/NEJMoa1310476] [PMID]
20. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Annals of the Rheumatic Diseases. 2022;81(6):798-804. [DOI:10.1136/annrheumdis-2021-221915] [PMID] []
21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery. 2021;88:105906. [DOI:10.1016/j.ijsu.2021.105906] [PMID]
22. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New England Journal of Medicine. 2012;367(6):508-19. [DOI:10.1056/NEJMoa1112072] [PMID]
23. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine. 2012;367(6):495-507. [DOI:10.1056/NEJMoa1109071] [PMID]
24. Kremer J, Li Z-G, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Annals of internal medicine. 2013;159(4):253-61. [DOI:10.7326/0003-4819-159-4-201308200-00006] [PMID]
25. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet. 2013;381(9865):451-60. [DOI:10.1016/S0140-6736(12)61424-X] [PMID]
26. Van Der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four-month phase III randomized radiographic study. Arthritis & Rheumatism. 2013;65(3):559-70. [DOI:10.1002/art.37816] [PMID]
27. Sands BE, Colombel J-F, Ha C, Farnier M, Armuzzi A, Quirk D, et al. Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management. Inflammatory bowel diseases. 2021;27(6):797-808. [DOI:10.1093/ibd/izaa227] [PMID] []
28. Álvaro-Gracia JM, García-Llorente JF, Valderrama M, Gomez S, Montoro M. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatology and Therapy. 2021;8:17-40. [DOI:10.1007/s40744-020-00258-9] [PMID] []
29. Yang X, Wan M, Cheng Z, Wang Z, Wu Q. Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):2775-82. [DOI:10.1080/21691401.2019.1573740] [PMID]
30. Charles‐Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis & rheumatology. 2015;67(3):616-25. [DOI:10.1002/art.38974] [PMID] []
31. Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nature Reviews Rheumatology. 2022;18(5):301-4. [DOI:10.1038/s41584-022-00767-7] [PMID] []
32. Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the rheumatic diseases. 2017;76(1):17-28. [DOI:10.1136/annrheumdis-2016-209775] [PMID]
33. Novikova DS, Udachkina HV, Markelova EI, Kirillova IG, Misiyuk AS, Demidova NV, et al. Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatology International. 2019;39(7):1181-9. [DOI:10.1007/s00296-019-04303-x] [PMID]
34. Hollan I, Ronda N, Dessein P, Agewall S, Karpouzas G, Tamargo J, et al. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal-Cardiovascular Pharmacotherapy. 2020;6(2):104-14. [DOI:10.1093/ehjcvp/pvz033] [PMID]
35. Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, et al. Challenges in the treatment of rheumatoid arthritis. Autoimmunity reviews. 2019;18(7):706-13. [DOI:10.1016/j.autrev.2019.05.007] [PMID]
36. Weber B, Liao KP, DiCarli M, Blankstein R. Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease. Current Opinion in Cardiology. 2021;36(5):549-55. [DOI:10.1097/HCO.0000000000000877] [PMID] []
37. Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets-a focus on the JAK-STAT pathway. Pain Research and Management. 2018;2018. [DOI:10.1155/2018/8564215] [PMID] []
38. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, Boy M, Zuckerman A, Soma K, et al., editors. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Seminars in arthritis and rheumatism; 2016: Elsevier. [DOI:10.1016/j.semarthrit.2016.05.014] [PMID]
39. Radin M, Arbrile M, Cecchi I, Di Nunzio P, Buccarano N, Di Gregorio F, et al. Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App. International Journal of Environmental Research and Public Health. 2022;19(9):5379. [DOI:10.3390/ijerph19095379] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
